[go: up one dir, main page]

NO20073629L - Terapeutiske formuleringer av keratinocyttvekstfaktor - Google Patents

Terapeutiske formuleringer av keratinocyttvekstfaktor

Info

Publication number
NO20073629L
NO20073629L NO20073629A NO20073629A NO20073629L NO 20073629 L NO20073629 L NO 20073629L NO 20073629 A NO20073629 A NO 20073629A NO 20073629 A NO20073629 A NO 20073629A NO 20073629 L NO20073629 L NO 20073629L
Authority
NO
Norway
Prior art keywords
growth factor
keratinocyte growth
therapeutic formulations
lyophilized
formulations
Prior art date
Application number
NO20073629A
Other languages
English (en)
Inventor
Michael J Treuheit
Vasumathi Dharmavaram
Judith Purtell
Suzanne E Roy
Original Assignee
Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab Publ filed Critical Biovitrum Ab Publ
Publication of NO20073629L publication Critical patent/NO20073629L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer langtidsstabile formuleringer av lyofilisert keratinocyttvekstfaktor og fremgangsmåter for å fremstille et lyofilisert preparat som omfatter keratinocyttvekstfaktor.
NO20073629A 2004-12-15 2007-07-13 Terapeutiske formuleringer av keratinocyttvekstfaktor NO20073629L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63621004P 2004-12-15 2004-12-15
PCT/US2005/045169 WO2006065861A2 (en) 2004-12-15 2005-12-12 Therapeutic formulations of keratinocyte growth factor

Publications (1)

Publication Number Publication Date
NO20073629L true NO20073629L (no) 2007-09-10

Family

ID=36337531

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073629A NO20073629L (no) 2004-12-15 2007-07-13 Terapeutiske formuleringer av keratinocyttvekstfaktor

Country Status (27)

Country Link
US (1) US8304387B2 (no)
EP (1) EP1827483B1 (no)
JP (1) JP5201992B2 (no)
KR (1) KR101283736B1 (no)
CN (1) CN101084008B (no)
AR (1) AR052339A1 (no)
AU (1) AU2005317166B2 (no)
BR (1) BRPI0519070A2 (no)
CA (1) CA2589889C (no)
CR (1) CR9246A (no)
DK (1) DK1827483T3 (no)
EA (1) EA013369B1 (no)
ES (1) ES2504441T3 (no)
HR (1) HRP20140926T1 (no)
IL (1) IL183435A (no)
MX (1) MX2007006822A (no)
MY (1) MY145638A (no)
NO (1) NO20073629L (no)
NZ (1) NZ555503A (no)
PL (1) PL1827483T3 (no)
PT (1) PT1827483E (no)
RS (1) RS53548B1 (no)
SI (1) SI1827483T1 (no)
TW (1) TWI351966B (no)
UA (1) UA88497C2 (no)
WO (1) WO2006065861A2 (no)
ZA (1) ZA200706095B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1827483E (pt) 2004-12-15 2014-09-25 Swedish Orphan Biovitrum Ab Publ Formulações terapêuticas do fator de crescimento de queratinócitos
US20090186805A1 (en) * 2006-07-06 2009-07-23 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
KR100784134B1 (ko) * 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
CN107041948A (zh) * 2009-01-21 2017-08-15 北京三有利科技发展有限公司 细胞生长因子治疗溃疡性疾病和肺纤维化疾病的应用
IT1396020B1 (it) * 2009-10-16 2012-11-09 Fitologica Srl Composizione topica a base di biopeptidi, e suo utilizzo in campo tricologico.
CN102675449B (zh) * 2011-03-17 2016-06-08 重庆富进生物医药有限公司 缺失型人角质细胞生长因子-ⅰ二硫键变构体及其用途
US20140287995A1 (en) * 2011-11-02 2014-09-25 The University Of Chicago Stable pharmaceutical formulations of growth factor peptides
CN102379838B (zh) * 2011-11-02 2013-06-12 广州舒泰生物技术有限公司 一种舒缓静颜化妆品的制备方法及应用
US20150126433A1 (en) * 2012-04-25 2015-05-07 University Of Cincinnati Growth factors for the treatment of mycobacterial infection
SG10201707600XA (en) 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
US10772942B2 (en) 2014-03-24 2020-09-15 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
CN108359634A (zh) * 2018-02-02 2018-08-03 江阴司特易生物技术有限公司 一种饲养细胞蛋白复合物及其应用
CN109402130A (zh) * 2018-11-23 2019-03-01 成都中医药大学附属医院 一种重组人角质细胞生长因子-1及其制备方法和用途
WO2020258893A1 (en) * 2019-06-24 2020-12-30 Hangzhou Dac Biotech Co., Ltd A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
CN110339345B (zh) * 2019-07-30 2022-11-29 重庆派金生物科技有限公司 一种重组人截短型角质细胞生长因子-1滴眼液及其制备方法和应用
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof
CN119632934A (zh) * 2025-02-19 2025-03-18 杭州熙岭生物科技有限公司 一种kgf-2组合物的冻干粉及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008771A1 (en) * 1989-01-31 1990-08-09 Rubin Jeffrey S Dna encoding a growth factor specific for epithelial cells
US7026291B1 (en) * 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
CA2125855C (en) * 1991-12-20 2008-05-13 Hans Holmegaard Sorensen A stabilized pharmaceutical formulation comprising growth hormone and histidine
AU681405B2 (en) * 1993-06-29 1997-08-28 Chiron Corporation A truncated keratinocyte growth factor (KGF) having increased biological activity
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
CA2202390C (en) 1994-10-13 2005-05-17 Bao-Lu Chen Keratinocyte growth factor analogs
CZ297329B6 (cs) 1994-10-13 2006-11-15 Amgen Inc. Analog nativního keratinocytového rustového faktoru kovalentne pripojený k polyethylenglykolu nebo príbuznému vodorozpustnému organickému polymeru, jeho pouzití a in vitro zpusob stimulace produkce nefibroblastových epithelových bunek
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
DK1516628T3 (da) * 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
DK1012186T3 (da) * 1996-12-06 2002-11-04 Amgen Inc Keratinocyt-vækstfaktorer og anvendelser deraf
US20020012961A1 (en) * 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
NZ505324A (en) * 1997-12-22 2002-11-26 Human Genome Sciences Inc Liquid and lyophilised KGF-2 polypeptide formulations used to accelerate soft tissue growth or regeneration
HK1045816A1 (zh) * 1999-06-02 2002-12-13 Human Genome Sciences, Inc. 角质细胞生长因子-2制剂
US6440414B1 (en) * 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
PT1827483E (pt) 2004-12-15 2014-09-25 Swedish Orphan Biovitrum Ab Publ Formulações terapêuticas do fator de crescimento de queratinócitos

Also Published As

Publication number Publication date
US8304387B2 (en) 2012-11-06
KR20070093977A (ko) 2007-09-19
CA2589889A1 (en) 2006-06-22
HK1115298A1 (en) 2008-11-28
IL183435A (en) 2010-11-30
MX2007006822A (es) 2007-07-24
SI1827483T1 (sl) 2014-11-28
IL183435A0 (en) 2007-09-20
AR052339A1 (es) 2007-03-14
HRP20140926T1 (hr) 2014-11-07
EP1827483A2 (en) 2007-09-05
NZ555503A (en) 2010-01-29
PT1827483E (pt) 2014-09-25
ES2504441T3 (es) 2014-10-08
AU2005317166B2 (en) 2009-09-10
JP5201992B2 (ja) 2013-06-05
KR101283736B1 (ko) 2013-07-08
MY145638A (en) 2012-03-15
JP2008524229A (ja) 2008-07-10
WO2006065861A2 (en) 2006-06-22
DK1827483T3 (da) 2014-10-06
EP1827483B1 (en) 2014-07-02
WO2006065861A3 (en) 2006-08-17
ZA200706095B (en) 2008-09-25
TW200635603A (en) 2006-10-16
EA200701293A1 (ru) 2008-02-28
EA013369B1 (ru) 2010-04-30
PL1827483T3 (pl) 2014-12-31
TWI351966B (en) 2011-11-11
CN101084008B (zh) 2013-04-10
BRPI0519070A2 (pt) 2008-12-23
CN101084008A (zh) 2007-12-05
US20060128622A1 (en) 2006-06-15
AU2005317166A1 (en) 2006-06-22
UA88497C2 (ru) 2009-10-26
CR9246A (es) 2007-10-23
RS53548B1 (sr) 2015-02-27
CA2589889C (en) 2013-07-30

Similar Documents

Publication Publication Date Title
NO20073629L (no) Terapeutiske formuleringer av keratinocyttvekstfaktor
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
ATE499109T1 (de) Zusammensetzung zur proteasomhemmung
NO20074179L (no) Prodrugs av 2,4-pyrimidindiaminforbindelser og deres anvendelse
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
WO2007037849A3 (en) Compositions and methods for the intraocular transport of therapeutic agents
NO20070699L (no) Spesielle aminoalkylglukosaminidfosfatforbindelser og deres anvendelse
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
IS7543A (is) Bensóþíadíasepínafleiður, aðferðir til framleiðslu þeirra og lyfjablöndur sem innihalda þær
TNSN07222A1 (en) Nematicidal compositions
WO2006030439A3 (en) Compositions and methods for inducing hair growth
FI20041704L (fi) Stabiilit mikrobisiirrosteet ja menetelmät niiden valmistamiseksi
CY1108797T1 (el) Α-κρυσταλλικη μορφη του ρανελικου στροντιου, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις που την περιεχουν
NO20072302L (no) Modulatorer av hepatocyttvekstfaktoraktivator
NO20065726L (no) Forbindelser og sammensetninger for avlevering av aktive forbindelser.
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
NO20042563L (no) Preparatsammensetning som inneholder syreustabile fysiologisk aktive forbindelser og fremgangsmater til fremstilling derav
MEP34308A (en) Oral formulations of cladribine
DK1810676T3 (da) Levetiracetam formuleringer og fremgangsmåder til deres fremstilling
NO20091771L (no) Ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat
BRPI0417205A (pt) composições farmacêuticas

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO

CREP Change of representative

Representative=s name: TANDBERGS PATENTKONTOR AS, POSTBOKS 1570 VIKA, 011

FC2A Withdrawal, rejection or dismissal of laid open patent application